Loading...
•
Mar 31, 2023
Lexicon Pharmaceuticals Q1 2023 Earnings Report
Lexicon Pharmaceuticals reported financial results for Q1 2023 and provided a business update.
Key Takeaways
Lexicon Pharmaceuticals reported a net loss of $31.9 million for the first quarter of 2023, compared to a net loss of $23.5 million for the corresponding period in 2022. As of March 31, 2023, Lexicon had $105.9 million in cash and investments.
NDA for sotagliflozin is on track for its May 27th, 2023 PDUFA date.
The company is prepared to promptly launch sotagliflozin in the United States in the first half of 2023, pending regulatory approval.
Lexicon continues preparations to advance LX9211 into late-stage development in neuropathic pain.
New analyses of results from the SOLOIST-WHF Phase 3 outcomes study of sotagliflozin were presented at the American College of Cardiology’s 72nd Annual Scientific Session.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...